Effect of oral postmenopausal hormone replacement on progression of atherosclerosis -: A randomized, controlled trial

hormone replacement therapy (HRT) is associated with low cardiovascular morbidity and mortality in epidemiological studies. Yet, no randomized trial has examined whether HRT is effective for prevention of coronary heart disease (CHD) in women with increased risk. The objective of this study was to determine whether HRT can slow progression of atherosclerosis, measured as intima-media thickness (IMT) in carotid arteries. Carotid IMT is an appropriate intermediate end point to investigate clinically relevant effects on atherogenesis. This randomized, controlled, observer-blind, clinical, single-center trial enrolled 321 healthy postmenopausal women with increased IMT in greater than or equal to1 segment of the carotid arteries. For a period of 48 weeks, subjects received either 1 mg/d 17 beta -estradiol continuously plus 0.025 mg gestodene for 12 days every month (standard-progestin group), or 1 mg 17 beta -estradio plus 0.025 mg gestodene for 12 days every third month (low-progestin group), or no HRT. Maximum IMT in 6 carotid artery segments (common, bifurcation, and internal, both sides) was measured by B-mode ultrasound before and after intervention. HRT did not slow IMT progression in carotid arteries. Mean maximum IMT in the carotid arteries increased by 0.02'0.05 mm in the no HRT group and by 0.03 +/-0.05 and 0.03 +/-0.05 mm, respectively, in the HRT groups (P>0.2). HRT significantly decreased LDL cholesterol, fibrinogen, and follicle-stimulating hormone. In conclusion, 1 year of HRT was not effective in slowing progression of subclinical atherosclerosis in postmenopausal